@article{oai:nagasaki-u.repo.nii.ac.jp:00020306,
 author = {Kasai, Takashi and Soda, Hiroshi and Oka, Mikio and Nakamura, Yoichi and Tsurutani, Junji and Nagashima, Seiji and Fukuda, Minoru and Takatani, Hiroshi and Fukuda, Masaaki and Kinoshita, Akitoshi and Kanda, Tetsuro and Kohno, Shigeru},
 issue = {3-4},
 journal = {Acta medica Nagasakiensia},
 month = {Dec},
 note = {Purpose: The present study was designed to determine whether the combination of carboplatin (CBDCA) with paclitaxel (PTX) spared CBDCA-induced thrombocytopenia by increased plasma thrombopoietin (TPO) levels. Methods: Patients with non-small-cell and small-cell lung cancer were consecutively assigned to CBDCA with PTX regimen (CBDCA/PTX) and CBDCA with irinotecan (CPT-11) regimen (CBDCA/CPT-11), respectively. Results: Ten patients were entered into either CBDCA/PTX (n=5) or CBDCA/CPT-11 (n=5). CBDCA/PTX showed a lesser reduction of platelet counts than CBDCA/CPT-11 (p<0.05), although more severe neutropenia was observed in CBDCA/PTX (p<0.01). The plasma TPO levels were inversely correlated with circulating platelet counts in CBDCA/PTX and CBDCA/CPT-11. However, the increased rate of plasma TPO levels in CBDCA/PTX was not significantly different from that in CBDCA/CPT-11. Conclusions: These findings suggest that the increased plasma TPO levels in CBDCA/PTX result secondarily from thrombocytopenia, and that circulating TPO is probably not involved in the platelet-sparing effect of PTX., Acta medica Nagasakiensia. 2003, 48(3-4), p.101-105},
 pages = {101--105},
 title = {Plasma Thrombopoietin Levels are Unlikely to Account for the Platelet-sparing Effect of Paclitaxel in Lung Cancer Patients},
 volume = {48},
 year = {2003}
}